$ESPR #Stocks #StockMarket #EsperionTherapeutics released Q1 EPS on https://t.co/savSNTKlN1: ESPR reported disastrous Q1, where Sales faded by -98.735 % to $1.840 MM and loss per share has widen at $-2.84, from the same quarter a year ago. https://t.co/uPtH1IgBib